Vive la resistant starch : A potential treatment for metabolic dysfunction-associated steatohepatitis

被引：0
|
作者：
Zhang, Xiang [1 ]
Yu, Jun [1 ]
Wong, Vincent Wai-Sun [1 ,2 ]
机构：
[1] Chinese Univ Hong Kong, Inst Digest Dis, State Key Lab Digest Dis, Hong Kong, Peoples R China
[2] Chinese Univ Hong Kong, Med Data Analyt Ctr, Dept Med & Therapeut, Hong Kong, Peoples R China
来源：
CELL METABOLISM | 2023年 / 35卷 / 09期
关键词：
D O I：
10.1016/j.cmet.2023.07.004
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
Metabolic dysfunction-associated steatotic liver disease is a prevalent chronic liver disease that affects nearly a third of the global adult population. Here, we preview a randomized controlled clinical trial on the potential benefits and underlying mechanisms of using resistant starch, a prebiotic, for treating this common liver condition.
引用
收藏
页码：1491 / 1493
页数：3
相关论文
共 50 条
  • [1] Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis
    Li, Xincheng
    Ayada, Ibrahim
    Li, Pengfei
    Pan, Qiuwei
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2025, 10 (02): : 108 - 109
  • [2] Nanoformulations for the diagnosis and treatment of metabolic dysfunction-associated steatohepatitis
    Qin, Xueying
    Liu, Jingjing
    ACTA BIOMATERIALIA, 2024, 184 : 37 - 53
  • [3] Epigenetics in metabolic dysfunction-associated steatohepatitis
    Zhang, Yanru
    Ding, Ruike
    Hu, Liangshuo
    Liu, Enqi
    Qu, Pengxiang
    CELLULAR SIGNALLING, 2025, 130
  • [4] Expanding the armamentarium for metabolic dysfunction-associated steatohepatitis
    Francque, Sven M.
    Vonghia, Luisa
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2024, 9 (12): : 1066 - 1067
  • [5] Resmetirom (Rezdiffra) for Metabolic Dysfunction-Associated Steatohepatitis
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2024, 66 (1701):
  • [6] Prediction of metabolic dysfunction-associated steatohepatitis resolution
    Loomba, Rohit
    Amangurbanova, Maral
    Bettencourt, Ricki
    Madamba, Egbert
    Siddiqi, Harris
    Richards, Lisa
    Gottwald, Mildred D.
    Feng, Shibao
    Margalit, Maya
    Huang, Daniel
    JOURNAL OF HEPATOLOGY, 2024, 80 : S522 - S523
  • [7] Cardiovascular Risk Reduction in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis
    Bernhard, Johannes
    Galli, Lukas
    Speidl, Walter S.
    Krychtiuk, Konstantin A.
    CURRENT CARDIOLOGY REPORTS, 2025, 27 (01)
  • [8] Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective
    Eskridge, Wayne
    Cryer, Donna R.
    Schattenberg, Joern M.
    Gastaldelli, Amalia
    Malhi, Harmeet
    Allen, Alina M.
    Noureddin, Mazen
    Sanyal, Arun J.
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (19)
  • [9] Metabolic dysfunction-associated steatohepatitis (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) require urgent attention by primary care physicians and endocrinologists
    Mauricio, Didac
    Escalada, Javier
    Perez, Antonio
    Romero-Gomez, Manuel
    Cusi, Kenneth
    Younoussi, Zobair M.
    Lazarus, Jeffrey V.
    ENDOCRINOLOGIA DIABETES Y NUTRICION, 2024, 71 (04): : 149 - 151
  • [10] Tirzepatide for treatment of metabolic dysfunction-associated steatohepatitis: relationship between metabolic and histological responses
    Caussy, C.
    Hartman, M. L.
    Thomas, M. K.
    Mather, K. J.
    Tang, Y.
    Loomba, R.
    Sanyal, A. J.
    DIABETOLOGIA, 2024, 67 : S121 - S121
12345